Readout 360

Oncology experts present and discuss recent data on frontline therapy options and outcomes for advanced metastatic clear cell and non-clear cell renal cell carcinoma, including considerations around optimal therapy for patients based on risk factors and disease sites, with a focus on understanding biology to develop improved histology-directed treatment approaches.

Three oncologists review recent clinical trial data presented at ASH 2023 on treatments for newly diagnosed multiple myeloma patients.

Three medical oncologists review recent clinical trial data presented at ESMO 2023 on treatments for patients with non–small cell lung cancer.

Expert panelists review clinical data from recent meetings regarding the updated management of renal cell carcinoma and consider how their real-world practice has been impacted.

Expert GU oncologists discuss recent data updates in the treatment of renal cell carcinoma from the ASCO 2023 Annual Meeting.

Three experts in gynecologic oncology review and discuss data updates from The Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer 2023.

Shaji Kumar, MD, Sandy Wong, MD, and Alexander Lesokhin, MD, review key data updates on the use of bispecific antibodies for the treatment of multiple myeloma presented at ASH 2022 and other recent meetings, and discuss how recent clinical trials have influenced treatment approaches in both the transplant-eligible and -ineligible patient populations.

A panel of experts review key data updates in renal cell carcinoma (RCC) from the International Kidney Cancer Association (IKCS) and European Society for Medical Oncology (ESMO) 2022 meetings and discuss how recent clinical trials are shaping the treatment of clear cell and non-clear cell RCC in clinical practice.

Drs Toni Choueiri and Robert J. Motzer reflect on recent data supporting the use of TKI/I-O combination regimens for frontline treatment of metastatic renal cell carcinoma.